Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11), FiscalAI reports.
Here are the key takeaways from Trevi Therapeutics’ conference call:
- Clinical programs remain on track: Trevi initiated the OCEAN-1 Phase III IPF-related chronic cough trial and LAKE-2b Phase II trial in refractory chronic cough during Q2, with OCEAN-2 planned for Q3. The company expects 50% enrollment in LAKE-2b during the second half of 2026.
- Trevi ended Q2 with approximately $319 million in cash, cash equivalents, and marketable securities and reiterated its cash runway into 2030, including funding for IPF development through potential approval, non-IPF ILD development through Phase III, and pre-commercial activities.
- The company views the termination of a competing refractory chronic cough program as improving its competitive position, potentially making Trevi the leading or only active developer across its three target cough indications. Management continues to estimate roughly 1 million U.S. treatment-resistant RCC patients as its initial commercial opportunity.
- Trevi is seeking FDA alignment on a non-IPF ILD-related chronic cough program and expects to learn this month whether an agency meeting has been granted. Management expects the eventual protocol to closely resemble the IPF program, but the regulatory path and number of required studies remain unresolved.
- The LAKE trial’s Q4 2026 sample-size re-estimation could require an increase of up to 50% if conditional power is below the company’s 80% threshold, potentially adding patients and affecting timelines, although management characterized this as a statistical adjustment rather than a sign of efficacy concerns.
Trevi Therapeutics Price Performance
Shares of Trevi Therapeutics stock traded up $0.01 on Friday, reaching $18.51. 2,175,078 shares of the company traded hands, compared to its average volume of 2,334,202. Trevi Therapeutics has a 52 week low of $6.55 and a 52 week high of $20.22. The company has a 50 day moving average of $16.97 and a 200 day moving average of $14.00. The firm has a market capitalization of $2.63 billion, a PE ratio of -54.44 and a beta of 1.03.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Trevi Therapeutics
Hedge Funds Weigh In On Trevi Therapeutics
Several institutional investors have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its holdings in Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares during the period. Strs Ohio purchased a new position in shares of Trevi Therapeutics during the 1st quarter valued at $52,000. Abel Hall LLC purchased a new position in shares of Trevi Therapeutics during the 4th quarter valued at $128,000. Rafferty Asset Management LLC bought a new position in shares of Trevi Therapeutics during the 2nd quarter worth $60,000. Finally, Creative Planning grew its stake in shares of Trevi Therapeutics by 17.5% during the 2nd quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after acquiring an additional 3,016 shares during the period. Hedge funds and other institutional investors own 95.76% of the company’s stock.
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
Read More
- Five stocks we like better than Trevi Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
